BR9713105A - Uso para os derivados de 1,3 - propanodiol - Google Patents

Uso para os derivados de 1,3 - propanodiol

Info

Publication number
BR9713105A
BR9713105A BR9713105-9A BR9713105A BR9713105A BR 9713105 A BR9713105 A BR 9713105A BR 9713105 A BR9713105 A BR 9713105A BR 9713105 A BR9713105 A BR 9713105A
Authority
BR
Brazil
Prior art keywords
prevention
optionally substituted
organ
tissue
derivatives
Prior art date
Application number
BR9713105-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Sylvain Cottens
Robert Paul Hof
Roland Wenger
Original Assignee
Novartis Ag Novartis Sa Movart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag Novartis Sa Movart filed Critical Novartis Ag Novartis Sa Movart
Publication of BR9713105A publication Critical patent/BR9713105A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Light Receiving Elements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9713105-9A 1996-11-19 1997-11-17 Uso para os derivados de 1,3 - propanodiol BR9713105A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (1)

Publication Number Publication Date
BR9713105A true BR9713105A (pt) 2000-04-11

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713105-9A BR9713105A (pt) 1996-11-19 1997-11-17 Uso para os derivados de 1,3 - propanodiol

Country Status (24)

Country Link
US (3) US6274629B1 (https=)
EP (2) EP0941082B1 (https=)
JP (2) JP4004070B2 (https=)
CN (2) CN1146411C (https=)
AT (2) ATE275947T1 (https=)
AU (1) AU728420B2 (https=)
BR (1) BR9713105A (https=)
CA (1) CA2270952C (https=)
CZ (1) CZ174999A3 (https=)
DE (2) DE69730727T2 (https=)
DK (1) DK1312359T3 (https=)
ES (2) ES2227726T3 (https=)
GB (1) GB9624038D0 (https=)
HU (1) HUP0000343A3 (https=)
ID (1) ID21568A (https=)
IL (1) IL129824A (https=)
NO (1) NO992259D0 (https=)
NZ (1) NZ335629A (https=)
PL (1) PL190348B1 (https=)
PT (2) PT941082E (https=)
RU (1) RU2217136C2 (https=)
SI (1) SI1312359T1 (https=)
SK (1) SK284806B6 (https=)
WO (1) WO1998022100A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1129066T3 (da) 1998-11-11 2005-03-29 Novartis Ag Fremstilling af 2-amino-2-[2-(C2-20alkylphenyl)ethyl]propan-1,3-dioler
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
US6995139B2 (en) * 2001-04-20 2006-02-07 Debiopharm S.A. Cyclic undecapeptide pro-drugs and uses thereof
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
PL1643983T3 (pl) * 2003-06-24 2010-10-29 Univ Connecticut Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
BRPI0619894B8 (pt) * 2005-12-15 2021-05-25 Mitsubishi Tanabe Pharma Corp composto de amina e composição farmacêutica
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US9815772B2 (en) * 2013-03-05 2017-11-14 Biocon Limited Process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
CN115477590B (zh) * 2021-05-31 2023-12-12 上海云晟研新生物科技有限公司 芬戈莫德药用盐、制备方法、含其的药物组合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE69321823T2 (de) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물

Also Published As

Publication number Publication date
ES2227726T3 (es) 2005-04-01
US20030069315A1 (en) 2003-04-10
EP1312359A3 (en) 2004-01-02
PL333463A1 (en) 1999-12-20
DE69738033T2 (de) 2008-04-30
SK65999A3 (en) 1999-12-10
SI1312359T1 (sl) 2008-08-31
CN1237906A (zh) 1999-12-08
HUP0000343A3 (en) 2001-06-28
PT1312359E (pt) 2007-11-09
RU2217136C2 (ru) 2003-11-27
GB9624038D0 (en) 1997-01-08
EP1312359B1 (en) 2007-08-15
ES2289041T3 (es) 2008-02-01
CN1293876C (zh) 2007-01-10
AU5483198A (en) 1998-06-10
ATE369846T1 (de) 2007-09-15
DK1312359T3 (da) 2007-10-08
JP2001503780A (ja) 2001-03-21
WO1998022100A2 (en) 1998-05-28
EP1312359A2 (en) 2003-05-21
HUP0000343A2 (hu) 2000-12-28
ID21568A (id) 1999-06-24
HK1022639A1 (en) 2000-08-18
PT941082E (pt) 2004-12-31
US6274629B1 (en) 2001-08-14
WO1998022100A3 (en) 1998-06-25
IL129824A (en) 2003-07-31
JP4004070B2 (ja) 2007-11-07
SK284806B6 (sk) 2005-11-03
JP2004256554A (ja) 2004-09-16
DE69730727D1 (de) 2004-10-21
CA2270952C (en) 2007-09-18
NO992259L (no) 1999-05-10
CZ174999A3 (cs) 1999-08-11
ATE275947T1 (de) 2004-10-15
CA2270952A1 (en) 1998-05-28
EP0941082B1 (en) 2004-09-15
DE69738033D1 (de) 2007-09-27
DE69730727T2 (de) 2005-09-22
NO992259D0 (no) 1999-05-10
EP0941082A2 (en) 1999-09-15
PL190348B1 (pl) 2005-11-30
IL129824A0 (en) 2000-02-29
CN1515253A (zh) 2004-07-28
US6486209B2 (en) 2002-11-26
AU728420B2 (en) 2001-01-11
US20010056124A1 (en) 2001-12-27
NZ335629A (en) 2001-09-28
CN1146411C (zh) 2004-04-21

Similar Documents

Publication Publication Date Title
BR9713105A (pt) Uso para os derivados de 1,3 - propanodiol
BR9811933A (pt) Vinil éteres heterocìclicos contra distúrbios neurológicos
BR9913952A (pt) Quimioterapia de câncer com acetildinalina em combinação com gemcitabina, capecitabina ou cisplatina
BR0109966A (pt) Combinação de compostos orgânicos
BR0116450A (pt) Composto, processos para a preparação de um carbamato, e para produzir um sal, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, produto de combinação
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
BR9815200A (pt) Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina
BR0109867A (pt) 2-guanidino-4-arilquinazolinas como inibidores de nhe-3
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
DE69912279D1 (de) 5-ht1f agonisten
BR9916576A (pt) Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2
ATE297945T1 (de) Glutathionderivate und dazugehörige dosisformen
BR0115949A (pt) Composição oral aquosa, estável, contendo zinco, tendo baixa adstringência, e, método para preparar a mesma
BR0015487A (pt) Compostos de imidazol como inibidores de fosfodiesterase vii
DK0640080T3 (da) Substituerede indoler som angiotensin II antagonister
ES8302783A1 (es) "un procedimiento para preparar un compuesto de inclusion de ciclodextrina".
BR9915879A (pt) Antagonista de receptor de vitronectina
DK671688A (da) 2-(piperazinyl)-2-oxoethylensubstituerede flavonoidderivater, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
BR9916188A (pt) Derivados de cromano
BR0110571A (pt) Método para preparar aminoisobutilalcoxissilano secundário
IT1298965B1 (it) Derivati dell'indolo atti all'impiego come composti cromogeni
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
ES2043820T3 (es) Nuevas 1-1 alkil-1-sulfonil-2-alkoxicarbonilsulfenilhidrazinas que tienen actividad antineoplastica.
EA200000697A1 (ru) ПРОИЗВОДНЫЕ БЕНЗО[C]ХИНОЛИЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5α-РЕДУКТАЗ
ES509554A0 (es) "procedimiento para la preparacion de nuevas cefalosporinas".

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/137, A61K 31/13, A61K 31/133, A61K 31/135, A61P 37/06, A61P 37/02

Ipc: A61K 31/137 (2007.10), A61K 31/13 (2007.10), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11, E 13 DALPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]